A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC - Trial NCT05775874
Access comprehensive clinical trial information for NCT05775874 through Pure Global AI's free database. This Phase 2 trial is sponsored by Abbisko Therapeutics Co, Ltd and is currently Recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Abbisko Therapeutics Co, Ltd
Timeline & Enrollment
Phase 2
Sep 30, 2022
Dec 30, 2025
Primary Outcome
Safety index,Effectiveness indicators
Summary
This trial is an open, phase II clinical study. The study is divided into two parts: A and B,
 and the part A evaluate the safety and tolerability of AZD4547 combined with Tislelizumab in
 patients with locally advanced or metastatic urothelial cancer, determine the recommended
 dose of midoral AZD4547 combined with Tislelizumab in a Chinese patient population. Part B
 study will evaluate the efficacy of this recommended dose combined with Tislelizumab in
 patients with locally advanced or metastatic urothelial cancer with FGFR2 / 3 alterations ,
 and will also further evaluate the safety, tolerability, and PK and PD characteristics of
 AZD4547 in combination with Tislelizumab.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05775874
Non-Device Trial